

INTEGRA LIFESCIENCES HOLDINGS CORP  
Form 8-K  
June 10, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 10, 2011**

Integra LifeSciences Holdings Corporation  
(Exact name of registrant as specified in its charter)

|  |                             |   |
|--|-----------------------------|---|
| Delaware   | 000-26244                   | 510317849                               |
| (State or other jurisdiction<br>of incorporation)                                  | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
| 311 Enterprise Drive, Plainsboro,<br>New Jersey                                    |                             | 08536                                   |
| (Address of principal executive<br>offices)  |                             | (Zip Code)                              |
| Registrant's telephone number, including area code: 609-275-0500<br>Not Applicable |                             |   |

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

*Private Offering*

In a press release issued on June 10, 2011, Integra LifeSciences Holdings Corporation (the Company ) announced the pricing of its offering of \$200 million aggregate principal amount of senior convertible notes due 2016 (the notes ) in a private placement, subject to market conditions and other factors. The Company has granted the initial purchasers of the notes options to purchase up to an additional \$30 million aggregate principal amount of the notes within 30 days of the initial issuance of the notes solely to cover over-allotments.

In accordance with Rule 135c(d) under the Securities Act, a copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statement and Exhibits.**

99.1 Press Release of Integra LifeSciences Holdings Corporation, dated June 10, 2011.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Integra LifeSciences Holdings Corporation

June 10, 2011

By: *Stuart M. Essig*  
Name: *Stuart M. Essig*  
Title: *Chief Executive Officer*

---

Exhibit Index

| <b>Exhibit No.</b> | <b>Description</b>                 |
|--------------------|------------------------------------|
| 99.1               | Press release issued June 10, 2011 |